scholarly journals Focus on the Tumour Periphery in MRI Evaluation of Soft Tissue Sarcoma: Infiltrative Growth Signifies Poor Prognosis

Sarcoma ◽  
2006 ◽  
Vol 2006 ◽  
pp. 1-5 ◽  
Author(s):  
Josefin Fernebro ◽  
Marie Wiklund ◽  
Kjell Jonsson ◽  
Pär-Ola Bendahl ◽  
Anders Rydholm ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Growth Pattern ◽  
Tumour Growth ◽  
Neoadjuvant Treatment ◽  
Soft Tissue Sarcomas ◽  
Prognostic Information ◽  
Diffuse Infiltration ◽  
Increased Risk ◽  
Tumour Periphery ◽  
Mri Evaluation

Purpose. Infiltrative microscopical peripheral growth of soft tissue sarcomas (STS) has been shown to be of prognostic importance and preoperative risk stratification could individualize neoadjuvant treatment.Patients and methods. We assessed peripheral tumour growth pattern on preoperative MRI from 78 STS. The findings were correlated to histopathology and to outcome.Results. The MRI-based peripheral tumour growth pattern was classified as pushing in 34 tumours, focally infiltrative in 25, and diffusely infiltrative in 19. All tumours with diffuse infiltration on MRI also showed microscopical infiltration, whereas MRI failed to identify infiltration in two-thirds of the microscopically infiltrative tumours. Diffusely infiltrative growth on MRI gave a 2.5 times increased risk of metastases (P=.01) and a 3.7 times higher risk of local recurrence (P=.02).Discussion. Based on this observation we suggest that MRI evaluation of STS should focus on the peripheral tumour growth pattern since it adds prognostic information of value for decisions on neoadjuvant therapies.

Prognostic Significance of Chromosome Aberrations in High-Grade Soft Tissue Sarcomas

2006 ◽  
Vol 24 (2) ◽  
pp. 315-320 ◽  
Author(s):  
Fredrik Mertens ◽  
Ulf Strömberg ◽  
Anders Rydholm ◽  
Pelle Gustafson ◽  
Henrik C.F. Bauer ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Chromosome Aberrations ◽  
Cox Regression ◽  
Prognostic Significance ◽  
Soft Tissue Sarcomas ◽  
Tumor Grade ◽  
High Grade ◽  
Prognostic Information ◽  
Cox Regression Analysis ◽  
Increased Risk

Purpose To investigate whether previously observed correlations between tumor karyotype and risk of metastases could be reproduced in an independent set of high-grade soft tissue sarcomas (STSs). Patients and Methods In a previous study on high-grade STSs with clonal chromosome aberrations, we identified a number of cytogenetic variables, besides tumor grade and size, that were associated with significantly increased risk of metastases. In the present study, we have tested the predictive value of these cytogenetic variables in a new set of 156 high-grade STSs, all located in the extremities or trunk wall. Results Of the 10 cytogenetic variables that turned out to provide prognostic information in the previous series, encompassing 122 trunk wall or extremity STSs, three were significantly associated with metastases also in the new series. In a final Cox regression analysis including these three cytogenetic variables, as well as tumor grade and size, on the combined series of 278 high-grade STSs, four parameters were found to be significantly associated with metastasis risk: tumor grade 3, tumor size ≥ 5 cm, breakpoint in region 1p1, and gain of region 6p1. Conclusion Our findings suggest that independent prognostic information may be gained from cytogenetic analysis of high-grade STS.

Sarcomas of Soft Tissue and Bone

2011 ◽  
Author(s):  
Adam Lerner ◽  
Huihong Xu ◽  
Karen H Antman
Keyword(s):  
Soft Tissue ◽  
Meta Analysis ◽  
Survival Rates ◽  
Fibrous Tissue ◽  
Soft Tissue Sarcomas ◽  
Kaposi Sarcoma ◽  
Uterine Leiomyosarcoma ◽  
Increased Risk ◽  
Bone Sarcomas ◽  
Epidemiologic Features

Sarcomas originate from bone or soft tissue. The most common bone sarcomas are osteosarcomas, Ewing sarcomas, and chondrosarcomas. Soft tissue sarcomas develop in fibrous tissue, fat, muscle, blood vessels, and nerves. Historically, soft tissue sarcomas of the trunk and extremities were reported separately from those of visceral organs (e.g., gastrointestinal and gynecologic sarcomas). This chapter discusses the classification, epidemiology, diagnosis, staging, and treatment of sarcomas of bone and cartilage, and classic soft tissue sarcomas. Management of Kaposi sarcoma, gastrointestinal stromal tumors (GISTs), mesothelioma, and rhabdomyosarcoma is also described. Figures include images of patients with osteosarcoma, liposarcoma, uterine leiomyosarcoma, GIST, and osteosarcoma in a patient with Paget disease of bone. Tables list epidemiologic features of sarcomas, a summary of sarcomas by histology, familial syndromes associated with increased risk of sarcoma, survival rates in sarcoma patients, staging of soft tissue sarcomas, and results of a meta-analysis of doxorubicin-based adjuvant chemotherapy for localized resectable soft tissue sarcoma. This chapter contains 126 references.

scholarly journals Growth pattern and differentiation of human soft tissue sarcomas in nude mice

Cancer ◽  
1981 ◽  
Vol 47 (1) ◽  
pp. 90-98 ◽  
Author(s):  
Steven I. Hajdu ◽  
Luciano B. Lemos ◽  
Harry Kozakewich ◽  
Lawrence Helson ◽  
Edward J. Beattie
Keyword(s):  
Soft Tissue ◽  
Nude Mice ◽  
Growth Pattern ◽  
Soft Tissue Sarcomas ◽  
Human Soft Tissue

scholarly journals The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets

2014 ◽  
Vol 34 (6) ◽  
Author(s):  
Laura Rocchi ◽  
Stefano Caraffi ◽  
Roberto Perris ◽  
Domenica Mangieri
Keyword(s):  
Soft Tissue ◽  
Tumour Growth ◽  
Therapeutic Targets ◽  
Soft Tissue Sarcomas ◽  
Specific Target ◽  
Target Therapies ◽  
New Therapeutic Targets

Angiogenesis is important for tumour growth and metastatization. The better understanding of the mechanisms of angiogenesis in soft tissue sarcomas can lead the design of specific target therapies for this group of poorly responding tumours.

scholarly journals Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma

Sarcoma ◽  
2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Shailaja Raj ◽  
Marilyn M. Bui ◽  
Gregory Springett ◽  
Anthony Conley ◽  
Sergio Lavilla-Alonso ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Neoadjuvant Treatment ◽  
Soft Tissue Sarcomas ◽  
External Beam Radiation ◽  
Serious Adverse Events ◽  
Clinical Safety ◽  
Beam Radiation ◽  
Clinical Responses

Purpose. Patients with large >5 cm, high-grade resectable soft tissue sarcomas (STS) have the highest risk of distant metastases. Previously we have shown that dendritic cell (DC) based vaccines show consistent immune responses.Methods. This was a Phase I single institution study of neoadjuvant radiation with DC injections on 18 newly diagnosed high-risk STS patients. Neoadjuvant treatment consisted of 50 Gy of external beam radiation (EBRT), given in 25 fractions delivered five days/week, combined with four intratumoral injections of DCs followed by complete resection. The primary endpoint was to establish the immunological response to neoadjuvant therapy and obtain data on its clinical safety and outcomes.Results. There were no unexpected toxicities or serious adverse events. Twelve out of 18 (67%) patients were alive, of which an encouraging 11/18 (61%) were alive with no systemic recurrence over a period of 2–8 years. Favorable immunological responses correlated with clinical responses in some cases.Conclusions. This study provides clinical support to using dendritic cell injections along with radiation in sarcomas, which when used optimally in combination can help clinical outcomes in soft tissue sarcoma. Study registration number isNCT00365872.

scholarly journals Neoadjuvant Treatment Options in Soft Tissue Sarcomas

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2061
Author(s):  
Mateusz Jacek Spałek ◽  
Katarzyna Kozak ◽  
Anna Małgorzata Czarnecka ◽  
Ewa Bartnik ◽  
Aneta Borkowska ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Neoadjuvant Therapy ◽  
Treatment Options ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Soft Tissue Sarcomas ◽  
Therapy Response ◽  
Response Assessment ◽  
Treatment Type ◽  
Therapy Response Assessment

Due to the heterogeneity of soft tissue sarcomas (STS), the choice of the proper perioperative treatment regimen is challenging. Neoadjuvant therapy has attracted increasing attention due to several advantages, particularly in patients with locally advanced disease. The number of available neoadjuvant modalities is growing continuously. We may consider radiotherapy, chemotherapy, targeted therapy, radiosensitizers, hyperthermia, and their combinations. This review discusses possible neoadjuvant treatment options in STS with an emphasis on available evidence, indications for each treatment type, and related risks. Finally, we summarize current recommendations of the STS neoadjuvant therapy response assessment.

Nuclear SMAD4 as a predictor of survival in patientes with extremity soft tissue sarcomas submitted to neoadjuvant chemotherapy.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 10586-10586
Author(s):  
Isabela Werneck Cunha ◽  
Ranyell Spencer Sobreira Batista ◽  
Paulo Roberto Stevanato ◽  
Samuel Aguiar ◽  
Ademar Lopes ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Soft Tissue Sarcomas ◽  
Disease Free Survival ◽  
Chemotherapy Response ◽  
Surgical Specimen ◽  
Viable Cells ◽  
Low Expression

10586 Background: Neoadjuvant chemotherapy for locally advanced soft tissue sarcomas, although not standard, represents a promising option for resectable tumours. The discovery of biological predictors of chemotherapy response highlights the possibility to develop individualised therapeutic approaches in selected group of patients or predict survival also. The SMAD4 protein, a member of TGFβ superfamily has a role in progression and tumor metastasis and may be involved sarcomas recurrence. Methods: 30 patients with soft tissue sarcomas (STS) of high-grade located in extremities treated with neoadjuvant doxorubicin and ifosfamide chemotherapy were observed prospectively since January 2005 to June 2011. All patients were submitted to radiation therapy adjuvant. Surgical specimens after neoadjuvant treatment were evaluated of SMAD4 nuclear expression by immuno-histochemistry and percentage of viable cells Results: The median follow-up time was 42 months. The overall survival (OS) was 91.7% in patients with low expression SMAD4 nuclear protein associated with ≤10% of viable cells (n=12) in the surgical specimen and 68.9% in the remaining patients. Likewise, the disease free survival (DSF) was 91.7% versus 38.6% (p 0.01) respectively. Conclusions: The combination of nuclear SMAD4 low expression and 10% or less of viable cells in the surgical specimen was statistically significant in better DFS in patients with locally advanced extremity STS treated with neoajuvant chemotherapy with benefit in OS.

Sarcomas of the Soft Tissue and Bone

2011 ◽  
Author(s):  
Adam Lerner ◽  
Huihong Xu ◽  
Karen H Antman
Keyword(s):  
Soft Tissue ◽  
Meta Analysis ◽  
Survival Rates ◽  
Fibrous Tissue ◽  
Soft Tissue Sarcomas ◽  
Kaposi Sarcoma ◽  
Uterine Leiomyosarcoma ◽  
Increased Risk ◽  
Bone Sarcomas ◽  
Epidemiologic Features

Sarcomas originate from bone or soft tissue. The most common bone sarcomas are osteosarcomas, Ewing sarcomas, and chondrosarcomas. Soft tissue sarcomas develop in fibrous tissue, fat, muscle, blood vessels, and nerves. Historically, soft tissue sarcomas of the trunk and extremities were reported separately from those of visceral organs (e.g., gastrointestinal and gynecologic sarcomas). This chapter discusses the classification, epidemiology, diagnosis, staging, and treatment of sarcomas of bone and cartilage, and classic soft tissue sarcomas. Management of Kaposi sarcoma, gastrointestinal stromal tumors (GISTs), mesothelioma, and rhabdomyosarcoma is also described. Figures include images of patients with osteosarcoma, liposarcoma, uterine leiomyosarcoma, GIST, and osteosarcoma in a patient with Paget disease of bone. Tables list epidemiologic features of sarcomas, a summary of sarcomas by histology, familial syndromes associated with increased risk of sarcoma, survival rates in sarcoma patients, staging of soft tissue sarcomas, and results of a meta-analysis of doxorubicin-based adjuvant chemotherapy for localized resectable soft tissue sarcoma. This chapter contains 126 references.

Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas

2013 ◽  
Vol 39 (1) ◽  
pp. 61-67 ◽  
Author(s):  
F. Grabellus ◽  
L.E. Podleska ◽  
S.-Y. Sheu ◽  
S. Bauer ◽  
C. Pöttgen ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Neoadjuvant Treatment ◽  
Soft Tissue Sarcomas ◽  
Fibrous Capsule ◽  
High Grade
Sign in / Sign up

Export Citation Format

Share Document